<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403622</url>
  </required_header>
  <id_info>
    <org_study_id>1410006671</org_study_id>
    <nct_id>NCT02403622</nct_id>
  </id_info>
  <brief_title>Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection</brief_title>
  <acronym>STOOL</acronym>
  <official_title>Safety of Fecal Microbiota Transplantation: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microbiome Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edward Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Microbiome Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching objective of this study is to address the knowledge gap regarding the&#xD;
      short-term and long-term safety of fecal microbiota transplants (FMT). The design will be a&#xD;
      prospective, open-label, multi-center longitudinal cohort study to assess the short- and&#xD;
      long-term safety of FMT as well as the clinical resolution of diarrhea among 150 patients&#xD;
      with 3 or more episodes of clostridium difficile infection (CDI defined as 3 unformed stools&#xD;
      over 24 hours for 2 consecutive days and either a positive stool test for CDI or&#xD;
      pseudomembranes on colonoscopy/sigmoidoscopy). Subjects will be adult outpatients referred to&#xD;
      one of the study centers after at least three recurrent episodes of CDI and previous&#xD;
      treatment with at least one 10-day course of oral vancomycin or fidaxomicin. After FMT by&#xD;
      colonoscopy/sigmoidoscopy or enema, patients will be followed prospectively and monitored for&#xD;
      clinical resolution and adverse events at: 3 days (telephone), 3 weeks (clinical assessment),&#xD;
      8 weeks (telephone), 6 months (telephone), and 12 months (telephone) after FMT. Subjects who&#xD;
      recur will be offered a second FMT by colonoscopy with a different donor. Microbiome analysis&#xD;
      will be conducted from stool samples at baseline and each of the 5 follow-up intervals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    for futility&#xD;
  </why_stopped>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term Safety of FMT as Measured by Absence or Presence of Related Serious Adverse Events</measure>
    <time_frame>&lt; 6 weeks post FMT</time_frame>
    <description>Determine the short-term safety of FMT for the prevention of further CDI recurrence. Short-term safety was measured by absence or presence of related serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Safety of FMT as Measured by Absence or Presence of Adverse Events</measure>
    <time_frame>&gt; 6 weeks to 1 year post FMT</time_frame>
    <description>Determine the long-term safety of FMT for the prevention of further CDI recurrence</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Clostridium Difficile</condition>
  <arm_group>
    <arm_group_label>Intervention: Fecal Microbiota Preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.&#xD;
Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal Microbiota Preparation</intervention_name>
    <description>Frozen processed human fecal material for treating recurrent Clostridium difficile infections.</description>
    <arm_group_label>Intervention: Fecal Microbiota Preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (age 18-75 years old)&#xD;
&#xD;
          -  Outpatient&#xD;
&#xD;
          -  Third or further documented CDI episode and&#xD;
&#xD;
          -  Unable to maintain CDI cure after standard therapy with oral vancomycin or fidaxomicin&#xD;
&#xD;
               -  Previous treatment with at least one course of tapered/pulse vancomycin or&#xD;
&#xD;
               -  Inability to taper or stop vancomycin or fidaxomicin without developing diarrhea&#xD;
                  requiring antibiotic therapy.&#xD;
&#xD;
          -  Improvement of CDI symptoms on vancomycin or fidaxomicin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to comply with study follow-up procedures at discretion of MD&#xD;
&#xD;
          -  Unable to provide informed consent at discretion of MD&#xD;
&#xD;
          -  Participating in another clinical trial&#xD;
&#xD;
          -  Pregnant or nursing currently or planned pregnancy in next 1 year&#xD;
&#xD;
          -  Evidence of toxic megacolon or gastrointestinal perforation&#xD;
&#xD;
          -  Peripheral white blood cell count &gt;30 x 10^9/L and/or temperature &gt;38 degrees Celsius&#xD;
&#xD;
          -  Admission to an intensive care unit within prior 7 days for any reason&#xD;
&#xD;
          -  Previously undergone FMT&#xD;
&#xD;
          -  Severely immunocompromised patients&#xD;
&#xD;
               -  HIV infection (any CD4 count)&#xD;
&#xD;
               -  AIDS-defining diagnoses&#xD;
&#xD;
               -  Inherited/primary immune disorder&#xD;
&#xD;
               -  Immunosuppressant medications:&#xD;
&#xD;
          -  Current or recent (&lt;3 months) treatment with anti-neoplastic agents&#xD;
&#xD;
          -  Current or recent (&lt;3 months) treatment with calcineurin inhibitors (tacrolimus,&#xD;
             cyclosporine)&#xD;
&#xD;
          -  Current or recent (&lt;3 months) treatment with mycophenolate mofetil&#xD;
&#xD;
          -  Current or recent (&lt;3 months) treatment with monoclonal antibodies to B and T-Cells,&#xD;
             anti-TNF, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine)&#xD;
&#xD;
          -  Neutropenia with absolute neutrophil count (ANC) &lt;0.5 x 10^9/L&#xD;
&#xD;
          -  Active gastroenteritis due to infectious cause other than CDI&#xD;
&#xD;
          -  Short gut syndrome&#xD;
&#xD;
          -  Colostomy&#xD;
&#xD;
          -  Ascites&#xD;
&#xD;
          -  End-stage liver disease&#xD;
&#xD;
          -  Untreated, in-situ colorectal cancer&#xD;
&#xD;
          -  Irritable bowel syndrome&#xD;
&#xD;
          -  Inflammatory bowel disease including Crohn's disease and ulcerative colitis&#xD;
&#xD;
          -  Microscopic colitis including collagenous colitis and lymphocytic colitis&#xD;
&#xD;
          -  Severe food allergy (anaphylaxis) that cannot be confirmed as having been excluded&#xD;
             from a donor's diet within the five days prior to donation&#xD;
&#xD;
          -  Anorectal disorder/severe rectal sphincter tone abnormality or inability to retain&#xD;
             enema material&#xD;
&#xD;
          -  Unable or unwilling to tolerate colonoscopy/sigmoidoscopy, colonoscopy prep, or enema&#xD;
             for any reason at discretion of MD&#xD;
&#xD;
          -  Severe underlying disease that the patient is not expected to survive for the&#xD;
             subsequent 12 months at the discretion of the MD.&#xD;
&#xD;
          -  Any conditions for which, in opinion of MD, the treatment may pose a health risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Edward Hospital</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <results_first_submitted>November 13, 2020</results_first_submitted>
  <results_first_submitted_qc>February 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <disposition_first_submitted>November 14, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>November 14, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 16, 2018</disposition_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 3, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02403622/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 17 participants enrolled (signed consents) across four sites during the period between March 27, 2015 and October 4, 2017.</recruitment_details>
      <pre_assignment_details>Two enrolled participants withdrew from the study prior to intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention: Fecal Microbiota Preparation</title>
          <description>Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.&#xD;
Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor&#xD;
Fecal Microbiota Preparation: Frozen processed human fecal material for treating recurrent Clostridium difficile infections.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population includes all participants who had enrolled (signed consent) in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention: Fecal Microbiota Preparation</title>
          <description>Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.&#xD;
Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor&#xD;
Fecal Microbiota Preparation: Frozen processed human fecal material for treating recurrent Clostridium difficile infections.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <title>18 to 35 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>35 to 55 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>55 to 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Short-term Safety of FMT as Measured by Absence or Presence of Related Serious Adverse Events</title>
        <description>Determine the short-term safety of FMT for the prevention of further CDI recurrence. Short-term safety was measured by absence or presence of related serious adverse events</description>
        <time_frame>&lt; 6 weeks post FMT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Fecal Microbiota Preparation</title>
            <description>Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.&#xD;
Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor&#xD;
Fecal Microbiota Preparation: Frozen processed human fecal material for treating recurrent Clostridium difficile infections.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Safety of FMT as Measured by Absence or Presence of Related Serious Adverse Events</title>
          <description>Determine the short-term safety of FMT for the prevention of further CDI recurrence. Short-term safety was measured by absence or presence of related serious adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Safety of FMT as Measured by Absence or Presence of Adverse Events</title>
        <description>Determine the long-term safety of FMT for the prevention of further CDI recurrence</description>
        <time_frame>&gt; 6 weeks to 1 year post FMT</time_frame>
        <population>Data were not collected therefore could not be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Fecal Microbiota Preparation</title>
            <description>Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.&#xD;
Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor&#xD;
Fecal Microbiota Preparation: Frozen processed human fecal material for treating recurrent Clostridium difficile infections.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Safety of FMT as Measured by Absence or Presence of Adverse Events</title>
          <description>Determine the long-term safety of FMT for the prevention of further CDI recurrence</description>
          <population>Data were not collected therefore could not be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>As outlined in the protocol, safety data were collected up to 12 months post-FMT. Due to study termination, not all participants were followed for the full 12 months, but instead an average of 11.7 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention: Fecal Microbiota Preparation</title>
          <description>Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.&#xD;
Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor&#xD;
Fecal Microbiota Preparation: Frozen processed human fecal material for treating recurrent Clostridium difficile infections.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pancreatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Splenectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bloating/Distention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increase in bowel movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue and malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CDI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>5th Metatarsal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thyrotoxicosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Graves' Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Laparoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Majdi Osman, MD, MPH</name_or_title>
      <organization>Microbiome Health Research Institute</organization>
      <phone>6175752201</phone>
      <email>mosman@openbiome.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

